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MethylationValproic acid (VPA) is a widely used antiepileptic drug and also prescribed to treat migraine, chronic headache
and bipolar disorder. Although it is usually well tolerated, a severe hepatotoxic reaction has been repeatedly re-
ported after VPA administration. A profound toxic reaction on administration of VPA has been observed in several
patients carrying POLGmutations, and heterozygous genetic variation in POLG has been strongly associatedwith
VPA-induced liver toxicity.
Here we studied the effect of VPA in fibroblasts of five patients carrying pathogenic mutations in the POLG gene.
VPA administration caused a significant increase in the expression of POLG and several regulators of mitochon-
drial biogenesis. It was further supported by elevatedmtDNA copy numbers. The effect of VPA onmitochondrial
biogenesis was observed in both control and patient cell lines, but the capacity of mutant POLG to increase the
expression of mitochondrial genes and to increase mtDNA copy numbers was less effective. No evidence of sub-
stantive differences in DNA methylation across the genome was observed between POLGmutated patients and
controls. Given the marked perturbation of gene expression observed in the cell lines studied, we conclude
that altered DNA methylation is unlikely to make a major contribution to POLG-mediated VPA toxicity. Our
data provide experimental evidence that VPA triggers increasedmitochondrial biogenesis by altering the expres-
sion of several mitochondrial genes; however, the capacity of POLG-deficient liver cells to address the increased
metabolic rate caused by VPA administration is significantly impaired.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Valproic acid (2-propyl-pentanoic acid, VPA) is a widely prescribed
antiepileptic drug used in several different types of epilepsy, but also in
other neurological conditions such as bipolar disease, migraine prophy-
laxis, alcohol andother sedative-hypnoticwithdrawal syndromes andoc-
casionally for chronic pain [1–3]. Although VPA is usually well tolerated,
severe hepatotoxic reaction including Reye-like liver failure and VPA-
induced hyperammonemic encephalopathy have been reported over
the last decades [2]. VPA toxicity can be fatal, particularly in children; mtDNA, mitochondrial DNA;
(OMIM: 203700);MIRAS,mito-
taxia, neuropathy, dysarthria,
ssive external ophthalmoplegia
BS, fetal bovine serum; NEAA,
VDF, polyvinylidene difluoride;
.
. This is an open access article underb2 years of age, thosewith developmental delay or thosewithmetabolic
disorders, such as deficiencies of the mitochondrial respiratory chain [4,
5]. The severity and frequently unexpected occurrence of VPA toxicity
has caused lot of debate about the application of this widely used medi-
cation and initiated major interest in solving the “mystery” of mecha-
nisms behind VPA toxicity. Although different pathways have been
suggested, no single cause has been identified to explain this reaction.
Mutations in themitochondrial DNA (mtDNA) polymerase γ (POLG)
cause variable neurological presentations such as Alpers–Huttenlocher
syndrome (AHS) [6], ataxia neuropathy spectrum including the pheno-
types previously referred to as mitochondrial recessive ataxia syndrome
(MIRAS), sensory ataxia, neuropathy, dysarthria, ophthalmoplegia
(SANDO) [7] and chronic progressive external ophthalmoplegia (CPEO)
plus parkinsonism [8]. A profound toxic reaction on administration of
VPA has been observed in several patients carrying POLG mutations,
and this observation provided a potential clue for unveiling, at least in
part, the mitochondrial mechanisms behind VPA toxicity. Children
with AHS due to autosomal recessive POLGmutations have a particular
predisposition to VPA toxicity. AHS is a childhood encephalopathythe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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disease [6,7]. Approximately 1/3 of AHS patients developed liver failure
within 3 months of exposure to VPA [9,10]. This raises the possibility
that genetic variation in POLG may predispose individuals to VPA-
induced liver failure who may not have a recognizable phenotype like
AHS [11]. In order to define the mechanism of VPA toxicity in POLG-
related disease, we performed further in vitro studies including a search
for an epigenetic mechanism, given the known role of VPA as a histone
deacetylase (HDAC) inhibitor.
2. Materials and methods
2.1. Patient cell lines
Primary human fibroblasts were selected from five POLG-deficient
patients (P1–P5) and three normal healthy controls (C1–C3) (Table 1).
Three POLG-mutant cell lines (P1, P2 and P3) were derived from un-
related patients with AHS secondary to compound heterozygous POLG
mutations: (i) P1: p.Gly737Arg and p.Ala767Asp; (ii) P2: p.Ala467Thr
and p.Ser1104Phe; and (iii) P3: p.Trp748Ser and c.3600delT. The re-
maining two POLG-deficient patient lines (P4 and P5) came from unre-
lated individuals with MIRAS secondary to (i) compound heterozygous
p.Ala467Thr and p.Trp748Ser POLGmutations (P4) and (ii) homozygous
p.Trp748Ser POLGmutation (P5). This study has the relevant ethical in-
stitutional approval and written informed consent was obtained from
all of the subjects involved.
2.2. Cell culture studies
Fibroblasts were cultured in MEM (Gibco) supplemented with
10% (v/v) FBS (Gibco) 50 U/ml penicillin and 50 μg/ml streptomycin
(Gibco), 1× MEM Vitamin Solution (Gibco), 1 mM sodium pyruvate
(Gibco), 1×NEAA (Gibco), 2mML-glutamine (Gibco) and 50 μg/ml uri-
dine nanopure (Sigma). Cells were grown in tissue culture flasks
(Greiner) at 37 °C in a humidified cell culture incubator containing
5% CO2. For both patients and controls, we used cells at similar passage
numbers (below 5). To investigate the effect of VPA on control and
POLG-affected fibroblasts, cells were cultured in media supplemented
with different VPA (Sigma) concentrations (0, 2, 5, 10 and 30 mM
VPA) and various time points (3, 6, 8 and 10 days). All the cells died
within few days of exposure to 30 mM VPA. At the same time, no obvi-
ous morphological changes were observed with 5 mM VPA after 10
days; hence, we decided on 10 mM to be the final VPA concentration
in our model system. Cell viability was assessed by daily observations
of morphology and density of fibroblasts using an inverted phase
contrast microscope (Leica). The cellular pellets were obtained from
(i) untreated fibroblast lines and (ii) cells cultured for 10 days in 10
mM VPA-supplemented growth media.
2.3. Immunoblotting
Fibroblast pellets were lysed in buffer containing the following:
5% (v/v) 1 M Tris (ph 7.5), 2.6% (v/v) 5 mM NaCl (VWR), 0.04% (v/v)Table 1
Properties of investigated cell lines derived from five POLG-positive patients and three healthy
Patient Age (years) Sex cDNA Consequence Pro
aff
P1 1 M c.2209 GNC; c.2300 CNA p.Gly737Arg; p.Ala767Asp LR
P2 5 M c.1399GNA; c.3311CNT p.Ala467Thr; p.Se1104Phe LR
P3 3 F c.2243GNC; c.3600delT p.Trp748Ser; c.3600delT LR
P4 39 M c.1399 GNA; c.2243GNC p.Ala467Thr; p.Trp748Ser LR
P5 36 M c.2243GNC; c.2243GNC p.Trp748Ser; p.Trp748Ser LR
C1 47 F − − −
C2 25 F − − −
C3 56 F − − −0.5 M MgCl2 (VWR), 1% (v/v) Triton™ X-100 (Sigma) and Complete™
protease inhibitor cocktail (Roche). The lysis mixture was then centri-
fuged at 1000g for 2 min at 4 °C. Protein concentrations were deter-
mined using Bradford assay (Bio-Rad) with BSA standards. Protein
samples (20 μg) were separated on 4–15% precast Tris–HCl gradient
gels (Bio-Rad), transferred to polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad) and immunoblotted with the following primary anti-
bodies: (i) rabbit monoclonal anti-POLG (Abcam, Cat.# ab128899;
1:2000), (ii) mouse monoclonal anti-SDHA (Abcam, Cat.# ab14715;
1:2000), (iii) mouse monoclonal anti-COX2 (Abcam, Cat.# ab110258;
1:2000) and (iv) rabbit polyclonal HRP-conjugated anti-GAPDH (Santa
Cruz, Cat.# sc-25778; 1:2000). Subsequently, membranes were
incubated with HRP-conjugated secondary antibodies.
2.4. Quantification of mtDNA copy numbers
Total genomic DNA was isolated from the cellular pellets using
DNeasy® Blood & Tissue Kits (Qiagen). The quantification of mtDNA
copy number was performed as previously described [12].
2.5. Gene expression studies
RNA was isolated from fibroblast pellets using RNeasy® Mini Kit
(Qiagen). cDNA was synthesized from isolated RNA using SuperScript™
III First-Strand Synthesis System (Invitrogen). Gene expression was de-
tected with SYBR® Green (Bio-Rad). Data were normalized to GAPDH
andACTB and analyzed using qBase Plus software (Biogazelle). Primer se-
quences for investigated genes are available upon request.
2.6. DNA methylation studies
Genomic DNA (500 ng) was bisulphite modified using EZDNA kits
(Zymo Research, CA, USA) according to manufacturer's instructions.
After random ordering, 200 ng bisulphite-converted modified DNA was
processed and analyzed using the Infinium HumanMethylation450
BeadChip assay (Illumina) to quantitatively determine DNAmethylation
status at more than 450K sites throughout the genome. Processing was
performed according to manufacturer's instructions. All samples passed
internal quality controls on the array, which included controls for
bisulphite conversion, hybridization and staining. Data pre-processing
and normalization were conducted using a previously developed analy-
sis pipeline [13]. Briefly, methylated or unmethylated signals that were
determined using 3 or fewer beads on the array were associated with
a detection P-value equal to 1. Samples with less than 80% of probes
with detection P-values of ≥0.01 were dropped from the analysis
(n = 19849). Probes containing SNPs were removed from the data
set (n = 17196). SNP data were obtained from the 1000 genomes
project and included SNPs with allele frequencies of ≥5% in the
European population [14]. Probes aligning to N1 genomic region,
allowing for 1 mismatch, were removed (n= 24707). X and Y chromo-
some probes were also removed from the analysis (n= 10578). Colour-
bias adjustment was made, based on a smooth quantile normalization
method developed in the R package Lumi. Background correction wascontrol individuals.
tein domain
ected
Detailed clinical phenotype
OA Epilepsy Ataxia Myopathy Neuropathy PEO Others
− + − + N/A − AHS
; PD − + + + N/A − AHS
; PD − + − + N/A − AHS
− − + − + + MIRAS
− − + − + + MIRAS
− − − − − − −
− − − − − − −
− − − − − − −
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quantile normalization was utilized, with a reference quantiles set
computed from Infinium I signals for each kind of probe category accord-
ing to the “relation to CpG” annotations provided by Illumina.
2.7. Statistical analysis
For the purpose of group comparisons, statistical analysis was per-
formed using GraphPad™ v.5 statistical software (GraphPad Software).
Group comparisons were considered to be statistically non-significant
(ns) if the calculated P-value was greater than 0.05, significant (*)
with P= 0.01 to 0.05, very significant (**) with P= 0.001 to 0.01 and
extremely significant (***) when the P-value was less than 0.001.
3. Results
3.1. Immunoblotting
In order to investigate the effect of a 10-day exposure to 10mMVPA
on the expression of mitochondria-associated proteins, western blot
analysis was performed on cell lysates from control and POLG-affected
individuals to look at the levels of (i) POLG, (ii) SDHA (nuclear-encoded
mitochondrial protein), (iii) COX2 (mtDNA-encoded protein) and
(iv) GAPDH (loading control) (Fig. 1A). The quantification of POLG levels
(Fig. 1B) revealed an unexpected 7-fold increase in its expression in
the VPA-treated controls when compared to control cells not exposed
to the drug. At the same time, VPA treatment resulted in an increase
in POLG level in only one POLG-deficient line (P1), whereas in the
remaining patient lines, POLG expression remained either constant
(P2 and P4) or significantly reduced (P3 and P4) when compared
to non-treated fibroblasts. Interestingly, the only POLG-mutated
line, which responded to VPA treatment with an increase in POLG
expression (P1), also revealed the highest POLG load of all patient
lines in normal basal conditions. However, the VPA-induced increaseC
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Fig. 1.Whole cell proteinwas isolated from the control and patientfibroblasts cultured for 10da
at 20 μg per lane were subjected to western blotting for POLG, SDHA, COX2 and GAPDH (A). T
GAPDH and quantified relatively to the untreated control (average of four controls). Western b
significance of the protein expression fold changes between VPA-untreated andVPA-treated ar
***P b 0.001.in POLG expression in the P1 line was only of 3-fold comparing to a
7-fold change observed in the controls. The protein expression levels
of SDHA, a protein that can be treated as the indicator of the mitochon-
drial mass, were significantly increased in all VPA-treated control and
patient lines (Fig. 1C). The levels of COX2 expression, a mitochondrial-
encoded subunit of complex IV, were significantly elevated in all VPA-
exposed lines, apart from P3, which however presented raised COX2
expression load even at basal conditions in normal culture medium.
3.2. Quantification of mtDNA copy numbers
In an attempt to evaluate the influence of exposure to VPA on
mtDNA copy number, we compared the relative mtDNA loads in fibro-
blasts after a 10-day culture with 10 mM VPA and without the drug,
both in control and in patient lines. Significant VPA-induced increase
in mtDNA copy number was observed in all investigated lines (apart
from P1); however, control cells revealed a more pronounced (4-fold)
elevation when compared to a maximal 2-fold increase presented by
POLG-affected lines (P4) (Fig. 2).
3.3. Gene expression studies
To investigate whether a 10-day exposure to 10 mM VPA had an
effect on the expression of mitochondria-associated genes, we deter-
mined expression patterns of selected genes involved inmtDNAmainte-
nance (POLG, POLG2, PEO1, POLRMT) (Figs. 3A, B, C and D, respectively),
mitochondrial biogenesis (PPARG, PGC-1α, TFAM) (Figs. 3E, F and G,
respectively) and OXPHOS (COX2) (Fig. 3H). Gene expression data re-
vealed that treatment of both control and patient cell lineswith VPApro-
motes a significant increase in the expression of all studied genes. In
particular, the expression of PGC-1α which encodes a master regulator
of mitochondrial biogenesis was markedly (N50-fold) elevated in VPA-
treated controls and POLG-affected fibroblast lines (Fig. 3F).P1
-V
PA
P2 P2
-V
PA
P3 P3
-V
PA
P4 P4
-V
PA
P5 P5
-V
PA
D
ys inpure basal (Normal) and 10mMVPA-supplemented (VPA-treated)media. Cell lysates
he levels of protein expression for POLG (B), SDHA (C) and COX2 (D) were normalized to
lot analysis is the representative of three independent biological replicates. The statistical
ms is indicated as follows: NS at P-value N 0.05; *P=0.01 to 0.05; **P= 0.001 to 0.01;
Fig. 2. RelativemtDNA copy number in control and patient fibroblasts cultured for 10 days
in pure basal (Normal) and 10mMVPA-supplemented (VPA-treated) media. The standard
deviationswere derived from the three independent technical replicates. The statistical sig-
nificance of the differences in mtDNA content between VPA-untreated and VPA-treated
arms is indicated as follows: NS at P-value N 0.05; *P= 0.01 to 0.05; **P= 0.001 to 0.01;
***P b 0.001.
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To explore whether VPA treatment induced any notable changes
in DNA methylation, differences in beta-values for 413,247 CpG sites
distributed throughout the genome were determined between VPA-
treated and non-treated (i) controls (Figs. 4A and C) and (ii) POLG-
deficient patients (Figs. 4B and D). No major changes in overall DNA
methylation patterns were present. We investigated the methylation
status for genes previously assessed in terms of their expression pat-
terns (section above) but found no significant change in CpG sites fol-
lowing multiple test correction (Table 2). Lastly, we compared the
number of (i) all, (ii) mitochondria, (iii) liver and (iv) both mitochon-
dria and liver-associated “top hit” CpG sites (i.e. where methylation
changed with more than 20% and more than 2-fold) between VPA-
treated controls and POLG-affected patients. No significant differences
were however present between these two cohorts (Table 3).4. Discussion
VPA is an 8-carbon 2-chain fatty acid, and it has been repeatedly
suggested to alter fatty acid metabolism through interference with mi-
tochondrial beta-oxidation [15]. A clear accumulation of long-chain
acyl-carnitines has been shown in control fibroblasts after 2 mM VPA
treatment for only 4 days [16]. Beside the competitive inhibition of
beta-oxidation enzymes, the depletion of carnitine [17], coenzyme A
[18] and glutathione [19] as an effect of VPAmetabolismwas suggested
to impair lipid metabolism resulting in steatosis. Oxidative stress has
been also proposed to contribute to VPA toxicity [19]. Very recently,
novel targetswere suggested to explainVPA-induced liver toxicity, show-
ing that the hyperammonemia observed in children under VPA treat-
ment may be a result of the direct inhibition of the N-acetylglutamate
activity by forming valproyl-CoA, and that the reduced availability of
N-acetylglutamate would impair the flux through the urea cycle and
compromise the major role of this pathway in ammonia detoxification
[5]. Another study highlighted that the cytotoxic action of VPA is medi-
ated by lysosomalmembrane leakiness alongwith reactive oxygen spe-
cies formation and a decline in the mitochondrial membrane potential
[3]. Although the exact metabolic pathways are not completely under-
stood, the metabolic profiling of organic acid and amino acid metabo-
lism suggested a potential age-related susceptibility to VPA toxicity [4].
Since the initial description of liver failure following VPA treatment
in AHS patients carrying POLGmutations numerous, similar cases havebeen described, leading to a statement recommending the avoidance
of valproic acid in children with a suspected POLG-related disease [10].
This poses a major clinical challenge due to the broad clinical spectrum
and variable age of onset of disease causedbymutations in POLG [10]. To
further complicate the scenario, heterozygous genetic variation in POLG
has been also strongly associatedwith VPA-induced liver toxicity [11]. It
was shown that although the role of 2 genetic variants, p.Q1236H and
p.E1143G in POLG-related disease, is not clear, these variants may be
disadvantageous in specific contexts, hypothetically such as exposure
to VPA. Primary cells of POLG patients and controls showed severely
compromised cellular proliferation when treated with VPA. Despite
the observed cell death, mtDNA copy numbers did not decrease, no de-
tectable mtDNA deletions were observed, no evidence of apoptosis was
noted and β-oxidation metabolites remained within normal limits [11].
Retrospective analysis of our previous data also supports an increase in
mtDNA copy numbers.
Unlike skeletalmuscle and brain, the liver can proliferate in response
to damage, and there is clear evidence of hepatocyte proliferation in pa-
tients with AHS. This raised the possibility that VPA compromises the
regenerative capacity of the liver, thus inhibiting the endogenous capac-
ity for liver repair in response to an external insult [11].
This being the case, why are patients with POLG mutations at in-
creased risk of VPA-hepatotoxicity? It has been previously suggested
that VPA inhibits histone deacetylases and alters methylation patterns
and therefore may affect the regulation of gene expression by relaxing
chromatin structure and facilitating access of the transcriptional ma-
chinery to the DNA [20]. In this study, we investigated whether VPA re-
sults in significant changes in gene expression or protein expression
profile of mitochondrial and/or liver-specific factors, which could be
due to epigenetic mechanisms such as DNA methylation. Although we
agree that liver cells of POLG-deficient patients would have been more
representative to study the hepatotoxic effect of VPA in vitro, the appli-
cation of primary human hepatocyte cultures is limited, because they
undergo a rapid dedifferentiation process [21]. Therefore, we performed
our investigations on primary human fibroblasts.
Based on the VPA-induced liver failure in patients with POLG-related
disease, we expected a negative effect of VPA on the expression of POLG
and other mitochondrial genes. However, our results indicated the op-
posite; VPA resulted in significant increase in the expression of POLG
and also several othermitochondrial proteins. Themost striking change
was a N50-fold increase in the gene expression of PGC-1α, which
encodes a master regulator of mitochondrial biogenesis. Since PGC-1α
is also a modulator of the expression of genes involved in fatty acid
metabolism, it is possible that its increased expression, at least in part
contributes to the previously reported accumulation of long-chain
acyl-carnitines in fibroblasts [16]. Another study showed that PGC-1α
overexpression was triggered by VPA in SH-SY5Y neuroblastoma cells
and upregulated expression of genes involved in mitochondrial func-
tion, glucose transport, fatty acid metabolism and synaptic function
[22]. In addition to PGC-1α, several other mtDNA maintenance genes
and mitochondrial proteins showed increased expression pattern,
confirming that, opposite to what we expected, VPA resulted in signifi-
cantly increased mitochondrial biogenesis, which was further support-
ed by the increased mtDNA copy numbers. These results suggest
that PGC-1α regulates multiple pathways and that VPA or other HDAC
inhibitorsmay be good candidates to target PGC-1α in human disorders.
The effect of VPA on mitochondrial biogenesis was observed both in
control and patient cell lines, but the capacity of mutant POLG to in-
crease the expression of mitochondrial genes and to elevate mtDNA
copy numbers was less effective. A similar mechanism in other mito-
chondrial conditionsmay explain the inability of themitochondrial res-
piration to adjust the demand of a higher respiratory rate triggered by
VPA administration. Recently, it has been shown, that valproyl-CoA af-
fects the activity of the succinate CoA ligase (SUCL) andmight influence
the activity of NDPK inducing an imbalance of nucleotides in the mito-
chondria [23].
Fig. 3. Gene expression measurements in control and patient fibroblasts cultured for 10 days in pure basal (Normal) and 10 mM VPA-supplemented (VPA-treated) media: (A) POLG,
(B) POLG2, (C) PEO1, (D) POLRMT, (E) PPARG, (F) PGC-1α, (G) TFAM and (H) COX2. The standard deviations were derived from the three independent technical replicates. The statistical
significance of the differences in gene expression between VPA-untreated and VPA-treated arms is indicated as follows: NS at P-value N 0.05; *P= 0.01 to 0.05; **P= 0.001 to 0.01;
***P b 0.001.
61K.S. Sitarz et al. / Molecular Genetics and Metabolism 112 (2014) 57–63Contrary to our hypothesis that differences in DNAmethylationmay
contribute to POLG-mediated VPA toxicity, no evidence of substantive
differences in DNA methylation across the genome (as measuredusing the Illumina HumanMethylation 450 BeadChip, which assays
around 1–2% of all CpG sites) was observed between POLGmutated pa-
tients and controls. We observed VPA-induced shifts of more than 20%
Fig. 4. Histograms showing changes in methylation between VPA-treated and non-treated: controls (A—absolute change; C—fold change) and POLG-mutated patients (B—absolute
change; D—fold change). All calculations are based on beta-values for 413,247 CpG sites.
62 K.S. Sitarz et al. / Molecular Genetics and Metabolism 112 (2014) 57–63in DNA methylation at several thousand CpG sites; however, none
surpassed the stringent threshold for genome-wide significance im-
posed, likely due to the small sample size. The observed differential
methylation is consistent with those seen in other contexts including
the alteration of DNA methylation in a VPA-treated neuroblastoma cell
line [24]. However, there were no discernible differences between the
response of controls and POLG mutated patients at these apparently
VPA-responsive loci. Given themarked perturbation of gene expression
observed in the cell lines studied, if DNAmethylationwere an important
mechanism of gene regulation in this context, we would have expected
differences between POLG and control cell lines to have been observed.Table 2
Analysis of the methylation status of probes selected within the loci of interest, as well as with
island. No CpG sites achieved statistical significance following multiple test correction (P b 0.0
Locus Chromosomal location (UCSC build 37) Region selected from 45
(region + (CpG Island
PEO1 chr10:102,747,293-102,754,158 chr10:102,744,534-102
CpG island chr10:102,746,534-102,747,501
POLG chr15:89,859,536-89,878,026 chr15:89,859,536-89,88
CpG island chr15:89,877,598-89,878,597
POLG2 chr17:62,473,902-62,493,184 chr17:62,473,902-62,49
CpG island chr17:62,492,883-62,493,323
POLRMT chr19:617,223-633,568 chr19:613,692-635,678
CpG island (intragenic) chr19:615,692-623,505
CpG island chr19:632,698-633,678
PPARG chr3:12,329,349-12,475,855 chr3:12,327,428-12,475
CpG island chr3:12,329,428-12,330,333
PGC1-α chr4:23,793,644-23,891,700 chr4:23,793,644-23,891
No local CpG islands
TFAM chr10:60,144,903-60,158,990 chr10:60,142,724-60,15
CpG island chr10:60,144,724-60,145,335We therefore conclude that altered DNA methylation is unlikely to
make a major contribution to POLG-mediated VPA toxicity, although it
may play a role in other mechanistic pathways culminating in adverse
responses to this drug.
In summary, our data provide experimental evidence that VPA
triggers increased mitochondrial biogenesis, probably through the in-
creased expression of several genes involved in these mechanisms.
We could not show any genome-wide differences in DNA methylation
patterns between POLGmutated patients and controls; VPA caused sim-
ilar changes in both patient and control cell lines. However, the capacity
of POLG-deficient cells to address the increased metabolic rate causedin CpG islands that were flanking each individual locus within 2kb of the distal end of the
5).
0K
+ 2kb))
Number of
analyzed probes
(CpG sites)
Absolute change in
methylation
following VPA
treatment
Fold change in
methylation
following VPA
treatment
Controls POLG Controls POLG
,754,158 23 −0.1% +0.1% 1.04 1.03
0,597 2 −6.7% +2.7% 0.91 1.08
5,323 8 −1.1% −0.7% 1.06 1.04
30 +2.2% −1.5% 1.08 1.04
,855 21 −1.7% −1.3% 1.07 1.04
,700 11 +1.9% +3.1% 1.11 1.08
8,990 13 −0.3% +0.1% 1.03 1.04
Table 3
Quantification of (i) all “top hit” CpG sites (i.e., those ones where methylation changed of
more of 20% and/or 2-fold) as well as (ii) mitochondria, (iii) liver and (iv) bothmitochon-
dria and liver-associated “top hit” CpG sites, in controls and POLG-affected patients. The
statistical comparisons between controls and patients were performed using two-tailed
chi-square test with Yates' correction. None of the group comparison appeared to be
statistically significant.
Controls POLG
patients
Controls
vs. patients
(P-values)
All “top hit” CpG sites 6898 7891 –
Mitochondria specific “top hit” CpG sites 263 314 0.632
Liver-associated “top hit” CpG sites 33 29 0.361
Mitochondria and liver-associated
“top hit” CpG sites
4 3 0.859
63K.S. Sitarz et al. / Molecular Genetics and Metabolism 112 (2014) 57–63by VPA administrationwas significantly impaired. Our data suggest that
by exhausting metabolic reserve capacity of the cells it may have a del-
eterious effect in POLG-related disease. By combining these results with
our previous data, we can propose the following model to explain VPA-
induced liver failure.We suggest that VPA triggers highermetabolic rate
and increased function of themitochondrial respiratory chain; however,
genetic defects (e.g. POLGmutations) prevent the optimal increase in
metabolism, by altering mtDNA replication or repair mechanisms.
Could VPA be beneficial by increasing mitochondrial biogenesis in
other forms of mitochondrial disease? Because of the high metabolic
rate and increased repair mechanisms in liver, VPA may more readily
exhaust endogenous hepatocellular regenerativemechanisms, especial-
ly if further compromised with altered mitochondrial accommodation
due tomutations in POLG. Further studies are needed to decide whether
similar mechanisms may be beneficial or rather harmful in other types
of mitochondrial disease.
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